Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
148.21
+12.01 (8.82%)
At close: Jun 26, 2026, 4:00 PM EDT
147.46
-0.75 (-0.51%)
After-hours: Jun 26, 2026, 5:20 PM EDT
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer |
| Mr. Jason Burdette | SVP of CMC & Technical Operations |
| Mr. Kent Taylor | Senior Vice President of Sales |
| Mr. Matthew E. Korenberg | CFO, Corporate Secretary & Treasurer |
| Mr. Wesley H. Kaupinen | Founder, President, CEO & Director |
| Ms. Ashley Hartmann Kline M.B.A. | Chief Commercial Officer |
| Ms. Bohan Wei | Vice President of Corporate Development & New Product Planning |
| Ms. Emily Cook | Senior Vice President of Clinical Operations |
| Ms. Kathleen Goin | Chief Operating Officer |
| Ms. Sarah Foster | Senior Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-06-16 | 8-K | tm2618003d1_8k.htm |
| 2026-05-20 | 8-K | pvla-20260520.htm |
| 2026-05-15 | 8-K | pvla-20260515.htm |
| 2026-05-13 | 8-K | pvla-20260511.htm |
| 2026-05-07 | 8-K | pvla-20260507.htm |
| 2026-05-07 | 10-Q | pvla-20260331.htm |
| 2026-04-30 | DEF 14A | tm261617-1_def14a.htm |
| 2026-04-13 | 8-K | pvla-20260413.htm |
| 2026-04-07 | 8-K | pvla-20260407.htm |
| 2026-03-31 | 8-K | pvla-20260331.htm |